Silence Therapeutics (NASDAQ:SLN) Releases Earnings Results

Silence Therapeutics (NASDAQ:SLN) posted its earnings results on Thursday. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14), Zacks reports. The business had revenue of $0.42 million during the quarter, compared to the consensus estimate of $1.26 million. Silence Therapeutics had a negative return on equity of 95.93% and a negative net margin of 8,943.86%.

Silence Therapeutics Stock Performance

Shares of SLN stock traded up $0.02 on Friday, reaching $6.97. The stock had a trading volume of 326,786 shares, compared to its average volume of 422,206. The stock has a market cap of $329.19 million, a P/E ratio of -4.38 and a beta of 1.52. Silence Therapeutics has a 1 year low of $3.56 and a 1 year high of $8.40. The company has a 50 day simple moving average of $6.41 and a 200 day simple moving average of $6.15.

Hedge Funds Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in Silence Therapeutics during the fourth quarter valued at $71,000. Quadrature Capital Ltd purchased a new position in Silence Therapeutics during the fourth quarter valued at $331,000. Opaleye Management Inc. purchased a new position in Silence Therapeutics during the fourth quarter valued at $480,000. Millennium Management LLC lifted its position in Silence Therapeutics by 121.0% during the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock valued at $4,010,000 after purchasing an additional 361,080 shares in the last quarter. Finally, ADAR1 Capital Management LLC lifted its position in Silence Therapeutics by 26.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after purchasing an additional 5,000 shares in the last quarter. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on SLN shares. HC Wainwright reissued a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Tuesday, April 21st. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, March 2nd. Finally, Jefferies Financial Group upgraded Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Silence Therapeutics has an average rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.